{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:58:23Z","timestamp":1770422303618,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.neurol.2023.01.727","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T09:54:52Z","timestamp":1684230892000},"page":"894-901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of risk management in a natalizumab home infusion procedure"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-0892","authenticated-orcid":false,"given":"J.-C.","family":"Lafontaine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7516-4670","authenticated-orcid":false,"given":"J.","family":"Giovannelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Petit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3197-373X","authenticated-orcid":false,"given":"O.","family":"Outteryck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Balagny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4029-2012","authenticated-orcid":false,"given":"H.","family":"Z\u00e9phir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neurol.2023.01.727_bib0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.neurol.2023.01.727_bib0100","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.neurol.2023.01.727_bib0105","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","article-title":"GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study","volume":"72","author":"Goodman","year":"2009","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2023.01.727_bib0110","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.neurol.2019.01.270","article-title":"Incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time","volume":"175","author":"Giovannoni","year":"2019","journal-title":"Revue Neurol."},{"issue":"20","key":"10.1016\/j.neurol.2023.01.727_bib0115","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.neurol.2023.01.727_bib0120","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2023.01.727_bib0125","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamaneurol.2019.2670","article-title":"Progressive multifocal leukoencephalopathy incidence and risk stratification among natalizumab users in France","volume":"77","author":"Vukusic","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2023.01.727_bib0130","doi-asserted-by":"crossref","first-page":"102842","DOI":"10.1016\/j.msard.2021.102842","article-title":"Reduction of the risk of PML in natalizumab treated MS patients in Sweden: an effect of improved PML risk surveillance","volume":"50","author":"K\u00e5gstr\u00f6m","year":"2021","journal-title":"Multiple Sclerosis Relat Disord"},{"issue":"12","key":"10.1016\/j.neurol.2023.01.727_bib0135","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1007\/s00415-020-10045-9","article-title":"Impact of COVID-19 on US and Canadian neurologists\u2019 therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices","volume":"267","author":"Mateen","year":"2020","journal-title":"J Neurol"},{"issue":"17","key":"10.1016\/j.neurol.2023.01.727_bib0140","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology"},{"issue":"Suppl. 1","key":"10.1016\/j.neurol.2023.01.727_bib0145","article-title":"PO112 MS patients\u2019 satisfaction with a home infusion service: a pilot study","volume":"88","author":"Brex","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.neurol.2023.01.727_bib0150","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2017-316074.79","article-title":"Establishment of the first at-home natalizumab infusion service for the treatment of relapsing remitting multiple sclerosis (rmms)","volume":"88","author":"Vijayan","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.neurol.2023.01.727_bib0155","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2018-ANZAN.22","article-title":"Piloting home infusions of natalizumab: a randomised crossover trial","volume":"89","author":"Schultz","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2023.01.727_bib0160","series-title":"jamovi. (Version 2.3) [Computer Software]","author":"The jamovi project","year":"2022"},{"key":"10.1016\/j.neurol.2023.01.727_bib0165","series-title":"R: a language and environment for statistical computing. (Version 4.1) [Computer software]","author":"R Core Team","year":"2021"},{"issue":"8","key":"10.1016\/j.neurol.2023.01.727_bib0170","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2023.01.727_bib0175","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neurad.2020.01.083","article-title":"New OFSEP recommendations for MRI assessment of multiple sclerosis patients: special consideration for gadolinium deposition and frequent acquisitions","volume":"47","author":"Brisset","year":"2020","journal-title":"J Neuroradiol"},{"key":"10.1016\/j.neurol.2023.01.727_bib0180","unstructured":"Tysabri summary of product characteristics, European medicines agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tysabri-epar-product-information_en.pdf."}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378723009438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378723009438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:47:38Z","timestamp":1758520058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378723009438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0035378723009438"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2023.01.727","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of risk management in a natalizumab home infusion procedure","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2023.01.727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}